



(51) International Patent Classification:

A61K 39/25 (2006.01) C12N 15/117 (2010.01)
C12N 15/113 (2010.01)

(21) International Application Number:

PCT/US2021/021544

(22) International Filing Date:

09 March 2021 (09.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/987,243 09 March 2020 (09.03.2020) US

(71) Applicant: DYNAX TECHNOLOGIES CORPORATION [US/US]; 2100 POWELL STREET, SUITE 900, EMERYVILLE, California 94608 (US).

(72) Inventors: CAMPBELL, John D.; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California 94608 (US). HYER, Randall N.; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California 94608 (US). JANSSEN, Robert S.; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California 94608 (US). NOVACK, David; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California 94608 (US).

(74) Agent: LEKUTIS, Christine et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: SHINGLES VACCINES COMPRISING A TLR9 AGONIST

(57) Abstract: The present disclosure relates to immunogenic compositions comprising a varicella zoster virus (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.




FIG. 1A

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*